IP Library Granted Patent US 7,887,795
Granted Patent B2
US 7,887,795 · App. 12/886,341 · Granted Feb 15, 2011

Methods of making enhanced, autologous fat grafts

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,887,795
App. No.
12/886,341
Granted
Feb 15, 2011
Kind
B2
Abstract

Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.

Claims (28)

1. A method of making an enhanced, autologous fat graft comprising:

extracting from a subject a first portion of adipose tissue to be used as a fat graft, then

supplementing said fat graft with an additive and a population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells, wherein said stem cells and endothelial precursor cells are prepared by disaggregating and concentrating the stem cells and endothelial precursor cells from a second portion of extracted adipose tissue from said subject, so as to make said enhanced, autologous fat graft.

2. The method of claim 1 , wherein said disaggregated adipose-derived stem cells and endothelial precursor cells are prepared by:

(a) disaggregating said second portion of extracted adipose tissue to generate a cell suspension; and

(b) separating a population of adipose-derived cells that comprises stem cells and endothelial precursor cells from the cell suspension by buoyant density sedimentation, filtration, or centrifugation.

3. The method of claim 2 , wherein the second portion of extracted adipose tissue is disaggregated in (a) by enzymatic digestion or mechanical force.

4. The method of claim 2 , further comprising reducing the presence of mature adipocytes in the cell suspension generated at step (a) prior to step (b).

5. The method of claim 2 , wherein the population of adipose-derived cells that comprises stem cells and endothelial precursor cells in (b) is separated by centrifugation.

6. The method of claim 5 , wherein the second portion of extracted adipose tissue is disaggregated in (a) by enzymatic digestion.

7. The method of claim 2 , wherein said population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells is prepared in a device that operates in a closed system.

8. The method of claim 1 , wherein said first portion of extracted adipose tissue is supplemented with said population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells in a device that operates in a closed system.

9. The method of claim 1 , wherein said first portion of extracted adipose tissue is supplemented with said additive and said population of concentrated, disaggregated, adipose-derived stem cells and endothelial precursor cells in a device that operates in a closed system.

10. The method of claim 1 , wherein said population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells is supplemented with said additive prior to supplementation of said first portion of extracted adipose tissue.

11. The method of claim 1 , wherein said population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells is not cultured.

12. A method of making an enhanced, autologous fat graft comprising:

(a) disaggregating a first portion of extracted adipose tissue with an enzyme or mechanical force to generate a cell suspension;

(b) concentrating the cells in said cell suspension by buoyant density sedimentation, filtration or centrifugation to obtain a population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells;

(c) supplementing said population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells with an additive;

(d) supplementing a second portion of extracted adipose tissue to be used as a fat graft with the population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells, so as to make said enhanced, autologous fat graft.

13. The method of claim 12 , wherein the population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells in (b) is prepared by centrifugation.

14. The method of claim 12 , wherein the population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells is prepared in a device that operates in a closed system.

15. The method of claim 12 , wherein said second portion of extracted adipose tissue is supplemented with said population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells in a device that operates in a closed system.

16. The method of claim 12 , further comprising reducing the presence of mature adipocytes in the cell suspension generated at step (a) prior to step (b).

17. The method of claim 12 , wherein said second portion of extracted adipose tissue is supplemented with said additive and said population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells in a device that operates in a closed system.

18. The method of claim 12 , wherein said population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells is supplemented with said additive prior to supplementing said second portion of extracted adipose tissue to be used as the fat graft with said population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells.

19. The method of claim 12 , wherein said population of concentrated, disaggregated adipose-derived stem cells and endothelial precursor cells is not cultured.

20. A method of making an enhanced, autologous fat graft, comprising extracting from a subject a first portion of adipose tissue to be used as a fat graft, then supplementing said fat graft with a population of concentrated, disaggregated adipose-derived stem cells and an additive, wherein the stem cells are prepared by disaggregating and concentrating the stem cells from a second portion of extracted adipose tissue from said subject, so as to make said enhanced, autologous fat graft.

Assignments (9)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 049313 FRAME: 0434. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 1, 2019
From: CYTORI THERAPEUTICS, INC.
To: LOREM VASCULAR PTE. LTD.
Reel/Frame 049942/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2019
From: CYTORI THERAPEUTICS, INC.
To: LOREM VASCULAR PTE. LTD.
Reel/Frame 049313/0434 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2019
From: CYTORI THERAPEUTICS, INC.
To: LOREM VASCULAR PTE. LTD.
Reel/Frame 049651/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2019
From: OXFORD FINANCE LLC
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 049011/0347 →
SECURITY INTEREST Recorded Sep 22, 2017
From: CYTORI THERAPEUTICS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 043952/0150 →
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2015
From: OXFORD FINANCE LLC
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 035902/0191 →
RELEASE OF SECURITY INTEREST Recorded Jul 3, 2013
From: GENERAL ELECTRIC CAPITAL CORPORATION
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 030734/0778 →
SECURITY AGREEMENT Recorded Jun 28, 2013
From: CYTORI THERAPEUTICS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 030715/0625 →
SECURITY AGREEMENT Recorded Dec 3, 2012
From: CYTORI THERAPEUTICS INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 029395/0660 →